Literature DB >> 7729633

Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers.

E Bayerdörffer1, S Miehlke, G A Mannes, A Sommer, W Höchter, J Weingart, W Heldwein, H Klann, T Simon, W Schmitt.   

Abstract

BACKGROUND/AIMS: Anti-Helicobacter pylori treatment with combinations of omeprazole and amoxicillin is a promising treatment option. The aim of this study was to investigate whether a daily omeprazole dose of 120 mg combined with amoxicillin would cure H. pylori infection at a rate comparable with that achieved with "triple therapy."
METHODS: In a double-blind, randomized, controlled, and multicenter trial in Germany, 270 patients with an H. pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131).
RESULTS: Cure rates of H. pylori infection were 91% in the omeprazole plus amoxicillin group, 0% in the omeprazole plus placebo group, and 89% and 0%, respectively, performing an intention-to-treat analysis. Cure of H. pylori infection in patients pretreated with omeprazole was only 58% compared with 95% in patients who were not. The cumulative 12-month relapse rates were 11.3% and 44% in the treatment groups and 1.6% in H. pylori-negative and 49% in H. pylori-positive patients.
CONCLUSIONS: The combination of 120 mg omeprazole daily and 2.25 g amoxicillin daily with its H. pylori cure rate of around 90% is one of the best tolerated and most effective treatment regimens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729633     DOI: 10.1016/0016-5085(95)90689-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  37 in total

Review 1.  Precise role of H pylori in duodenal ulceration.

Authors:  Michael Hobsley; Frank I Tovey; John Holton
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

2.  Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy.

Authors:  G Manes; O Pieramico; F Perri; D Vaira; N Giardullo; M Romano; G Nardone; A Balzano
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

3.  CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability.

Authors:  T Kita; Y Tanigawara; N Aoyama; T Hohda; Y Saijoh; F Komada; T Sakaeda; K Okumura; T Sakai; M Kasuga
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

4.  Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.

Authors:  Rocco Maurizio Zagari; Gabriele Bianchi-Porro; Roberto Fiocca; Giovanni Gasbarrini; Enrico Roda; Franco Bazzoli
Journal:  Gut       Date:  2006-10-06       Impact factor: 23.059

5.  High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection.

Authors:  Kadir Öztürk; Ömer Kurt; Gürkan Çelebi; Hakan Şarlak; Muhammed Fatih Karakaya; Hakan Demirci; Ali Kılınç; Ahmet Uygun
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

Review 6.  Potent gastric acid inhibition in Helicobacter pylori eradication.

Authors:  Javier P Gisbert
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-02-14       Impact factor: 4.291

8.  Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates.

Authors:  Seung Bae Yoon; Jae Myung Park; Jong-Yul Lee; Myong Ki Baeg; Chul-Hyun Lim; Jin Soo Kim; Yu Kyung Cho; In Seok Lee; Sang Woo Kim; Myung-Gyu Choi
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 9.  Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people.

Authors:  Alexander C Ford; Kurinchi Selvan Gurusamy; Brendan Delaney; David Forman; Paul Moayyedi
Journal:  Cochrane Database Syst Rev       Date:  2016-04-19

10.  Gastric mucosal inflammatory responses toHelicobacter pylori lipopolysaccharide: suppression of caspase-3 and nitric oxide synthase-2 by omeprazole and sucralfate.

Authors:  B L Slomiany; J Piotrowski; A Slomiany
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.